US5565200A - Pharmaceutical preparations derived from korean mistletoe - Google Patents
Pharmaceutical preparations derived from korean mistletoe Download PDFInfo
- Publication number
- US5565200A US5565200A US08/422,438 US42243895A US5565200A US 5565200 A US5565200 A US 5565200A US 42243895 A US42243895 A US 42243895A US 5565200 A US5565200 A US 5565200A
- Authority
- US
- United States
- Prior art keywords
- extract
- mistletoe
- binding proteins
- dependent
- sugar
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Expired - Fee Related
Links
Images
Classifications
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
- C07K14/415—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from plants
- C07K14/42—Lectins, e.g. concanavalin, phytohaemagglutinin
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K36/00—Medicinal preparations of undetermined constitution containing material from algae, lichens, fungi or plants, or derivatives thereof, e.g. traditional herbal medicines
- A61K36/18—Magnoliophyta (angiosperms)
- A61K36/185—Magnoliopsida (dicotyledons)
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K38/00—Medicinal preparations containing peptides
- A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
- A61K38/168—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from plants
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
- C07K14/415—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from plants
Abstract
Description
TABLE 1 ______________________________________ COMPOSITION REQUIREMENTS FOR PHARMA- CEUTICAL GRADE KOREAN MISTLETOE EXTRACT Percentage By Weight of Total Protein in Extract ______________________________________ (Ca.sup.++ dependent sugar-binding proteins) 1. Lactose 0.1-0.5 2. Galactose 0.1-0.5 3. Melibiose 0.1-0.5 4. N-Acetyl-D-galactosamine 0.1-0.5 5. Fucose 0.1-0.5 (Non-Ca.sup.++ dependent sugar-binding proteins) 1. Lactose 0.1-0.5 2. Galactose 0.1-0.8 3. Melibiose 0.1-0.5 4. N-Acetyl-D-galactosamine 0.1-0.7 5. Fucose 0.1-0.5 ______________________________________
TABLE 2 ______________________________________ COMPOSITION REQUIREMENTS FOR PHARMA- CEUTICAL GRADE KOREAN MISTLETOE EXTRACT Inhibitory Concentration Activity (mg/ml) (ID.sub.50) ______________________________________ (Ca.sup.++ dependent sugar- binding proteins) 1. Lactose 0.1-0.5 0.1-0.5 2. Galactose 0.2-0.6 0.1-0.5 3. Melibiose 0.1-0.5 0.1-0.5 4. N-Acetyl-D-galactosamine 0.5-1.0 0.1-0.5 5. Fucose 0.1-0.5 0.1-0.5 (Non-Ca.sup.++ dependent sugar- binding proteins) 1. Lactose 0.1-0.5 0.0001-0.009 2. Galactose 1.0-2.0 0.001-0.01 3. Melibiose 0.1-0.5 0.001-0.01 4. N-Acetyl-D-galactosamine 0.5-1.0 0.001-0.1 5. Fucose 1.0-2.0 0.001-0.1 ______________________________________
TABLE 3 ______________________________________ BIOLOGICAL ACTIVITY OF MISTLETOE EXTRACTS IN TERMS OF ACTIVITY UNITS (A.U.) Activity units/ml, Sample Identity (1% Extract) ______________________________________ 1. ISCADOR M, Arg., 10% 80 2. n-T4GEN, 40% 400 3. ISCADOR M, 5% 30 4. ISCADOR M, 20% 37 5. T4GEN, 1% 140 6. T4GEN, 10% 217 7. ISCADOR M, 20% 26 8. n-T4GEN, 40% 416 9. n-T4GEN 192 10. n-T4GEN 811 ______________________________________ Activity unit per ml = concentration of sample in μg/ml ID.sub.50 (μg/ml). ______________________________________
______________________________________ Effect of Korean Mistletoe Extract on the Infectivity of HIV to H9 Lymphoma Cells in Culture Cytopathic Effects Reverse Transcriptase n-T4GEN* (Syncytia cells) (cpm) (μg/ml) Day 5 Day 10 ______________________________________ 0.01 ++ 97,896 (100) 0.10 ++ 77,971 (79) 1.00 ++ 65,932 (67.3) 10.00 ± 32,128 (32.8) 100.00 (toxic) 4,200 ______________________________________ H9 lymphoma cells growing in RPMI1640 media containing 10% fetal calf serum were infected with HIV (100,000 RT counts) on day 1 and various concentrations of nT4GEN extract. On day 5 cells were observed for cytopathic effects (syncytia), and on day 10 assayed for RT activity. (++ Denotes extensive giant cells, (±) fewer syncytial cell. *Amounts expressed as μg/ml of 1 percent extract.
______________________________________ Effect of n-T4GEN on the Growth of Subcutaneous Transplants of C3H Mammary Adenocarcinoma 16/C in B6C3F1, Female Mice Tumor Tumor Tumor Free Treatments Δ Wts (g) Wts Inhibition Animals i.p. (day 14) (day 21) % (day 93) ______________________________________ 1. Saline, Controls +0.21 0.27 -- 1/15 2. n-T4GEN* 0.25 ml/kg, +1.33 0.15 44 1/10 qd (1-14) 0.5 ml/kg, +0.73 0.18 33 3/10 qd (1-14) 3. 5Fluorouracil 98 mg/kg, +1.77 0.00 100 0/6 qd (1,7,14,21) ______________________________________ *Amounts expressed as ml of 1 percent extract.
TABLE 4 __________________________________________________________________________ FRACTIONATION OF THE VARIOUS CONSTITUENTS OF V. ALBUM COLORATUM WITH ANTILEUKEMIA -- L1210 ACTIVITY -- n-T4GEN (40%) (Affinity Method, Fractionation of Salt Extract) Protein Content Total Volume Total Protein ID.sup.a.sub.50 Total Activity.sup.b Fraction identity (mg/ml) (ml) (mg) (μg Protein/ml) Units __________________________________________________________________________ Salt Extract 7.63 350 2673 0.11 2.4 × 10.sup.7 Affinity columns eluted with EDTA buffer -- Ca.sup.++ dependent 1. Lactose 0.31 20 6.24 0.38 1.6 × 10.sup.4 2. Galactose 0.39 20 7.91 0.25 3.1 × 10.sup.4 3. Melibiose 0.28 20 5.44 0.20 2.7 × 10.sup.4 4. N-Acetyl-D-galactosamine 0.70 12.5 875 0.29 3.00 × 10.sup.4 5. Fucose 0.28 18 5.04 0.36 1.4 × 10.sup.4 Affinity columns eluted with corresponding sugars -- non- Ca.sup.++ dependent 1. Lactose 0.27 22 5.98 0.00027 2.2 × 10.sup.7 2. Galactose 1.40 9 12.60 0.0013 9.6 × 10.sup.6 3. Melibiose 0.32 10 3.20 0.0034 9.4 × 10.sup.5 4. N-Acetyl-D-galactosamine 0.66 18 11.90 0.017 7.0 × 10.sup.5 5. Fucose 1.17 15 2.59 0.019 1.3 × 10.sup.5 Sephadex -- G75 (Unbound proteins) Fractions.sup.c I (12-50) 1.84 46 84.6 0.5 1.69 × 10.sup.5 II (51-70) 1.22 22.5 27.45 4.0 6.8 × 10.sup.3 III (71-100) 1.12 40 44.80 2.8 1.6 × 10.sup.4 IV (101-140).sup.d 0- 50 0- 13.5 1.6 × 10.sup.4 __________________________________________________________________________ .sup.a Inhibitory concentration expressed as μg protein/ml which cause 50% inhibition of the growth of L1210 cells in culture. .sup.b Activity unit is defined as dilution factor needed for a specific fraction which when added to L1210 cells caused a 50% cell growth inhibition. .sup.c 50 ml on column from a total eluate of 325 ml. .sup.d 31 mg alkaloids obtained from fraction IV.
TABLE 5 __________________________________________________________________________ FRACTIONATION OF THE VARIOUS CONSTITUENTS OF V. ALBUM COLORATUM WITH ANTILEUKEMIA -- L1210 ACTIVITY -- n-T4GEN (40%) (Affinity Method, Fractionation of Detergent Extract) Protein Content Total Volume Total Protein ID.sup.a.sub.50 Total Activity.sup.b Fraction Identity (mg/ml) (ml) (mg) (μg Protein/ml) Units __________________________________________________________________________ Detergent Extract 1.68 450 756 0.27 2.8 × 10.sup.6 Affinity columns eluted with EDTA buffer 1. Lactose 0.18 22 4.04 0.250 1.6 × 10.sup.4 2. Galactose 0.08 11.5 0.97 0.031 3.1 × 10.sup.4 3. Melibiose 0.16 20 3.12 0.054 5.7 × 100.sup.4 4. N-Acetyl-D-galactosamine 0.17 19 3.20 0.076 4.2 × 10.sup.4 5. Fucose 0.12 6.5 0.78 0.100 0.5 × 10.sup.4 Affinity columns eluted with corresponding sugars 1. Lactose 0.35 95 3.23 0.0045 2.1 × 10.sup.6 2. Galactose 050 15 7.50 0.0055 1.3 × 10.sup.6 3. Melibiose 0.15 12 0.61 0.0084 0.07 × 10.sup.6 4. N-Acetyl-D-galactosamine 0.62 4 7.68 0.0035 2.1 × 10.sup.6 5. Fucose 0.50 10 5.10 0.0500 0.1 × 10.sup.6 Sephadex -- G75 (Unbound proteins) Fractions.sup.c I (9-35) 1.58 33 52.1 1.25 0.05 × 10.sup.6 II (36-55) 1.36 20 27.2 1.70 0.008 × 10.sup.6 3 III (56-120).sup.d 0- 50 0- 14.00 0.002 × 10.sup.6 __________________________________________________________________________ .sup.a Inhibitory concentration expressed as μg protein/ml which cause 50% inhibition in the growth of L1210 cells in culture. .sup.b Activity unit is defined as dilution factor needed for a specific fraction which when added to L1210 cells caused a 50% inhibition. .sup.c 50 ml on column from a total of 420 ml. .sup.d 22 mg alkaloids obtained from fraction III.
TABLE 6 __________________________________________________________________________ FRACTIONATION OF DIFFERENT BIOLOGICALLY ACTIVE CARBOHYDRATE BINDING PROTEINS FROM VISCUM ALBUM C. EXTRACT (40%, FrF) (n-T4GEN) Total Volume Total Protein ID.sub.50.sup.a Total Activity Fraction identity (ml) (mg) ID.sub.50.sup.a (μg/ml) Units.sup.b __________________________________________________________________________ Extract (40%, FrF) 90 234 32,500 2.92 × 10.sup.6 Affinity columns eluted with EDTA buffer 1. Lactose 5.5 4.29 175 1.10 0.10 × 10.sup.4 2. Galactose 11.5 2.10 415 0.49 0.50 × 10.sup.4 3. Melibiose 10 1.36 315 0.40 0.30 × 10.sup.4 4. N-Acetyl-D-galactosamine 7 0.95 400 0.33 0.28 ×3 10.sup.4 5. Fucose 5 1.82 365 1.00 0.18 × 10.sup.4 Affinity columns eluted with buffer containing corresponding sugars 1. Lactose 8 2.24 208,000 0.001 1.66 × 10.sup.6 2. Galactose 11 2.68 68,000 0.0035 0.75 × 10.sup.6 3. Mibiose 6.5 0.96 5,600 0.025 0.036 × 10.sup.6 4. N-Acetyl-D-galactosamine 4.5 0.81 49,000 0.0035 0.22 × 10.sup.6 5. Fucose 5 0.33 10,500 0.0056 0.052 × 10.sup.6 Unbound proteins and alkaloids 168 285 1,600 1.25 0.27 × 10.sup.6 __________________________________________________________________________ .sup.a Dilution factor needed per ml to cause 50% inhibition of L1210 cells in culture. .sup.b Activity unit is defined as dilution factor needed for a specific fraction which when added to L1210 cell will cause 50% inhibition of the cell growth.
Claims (12)
Priority Applications (4)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
US08/422,438 US5565200A (en) | 1995-04-14 | 1995-04-14 | Pharmaceutical preparations derived from korean mistletoe |
PCT/US1996/004577 WO1996032123A1 (en) | 1995-04-14 | 1996-04-03 | Pharmaceutical preparations derived from korean mistletoe |
AU55327/96A AU5532796A (en) | 1995-04-14 | 1996-04-03 | Pharmaceutical preparations derived from korean mistletoe |
CA002174031A CA2174031C (en) | 1995-04-14 | 1996-04-12 | Benzoyl peroxide compositions |
Applications Claiming Priority (1)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
US08/422,438 US5565200A (en) | 1995-04-14 | 1995-04-14 | Pharmaceutical preparations derived from korean mistletoe |
Publications (1)
Publication Number | Publication Date |
---|---|
US5565200A true US5565200A (en) | 1996-10-15 |
Family
ID=23674887
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
US08/422,438 Expired - Fee Related US5565200A (en) | 1995-04-14 | 1995-04-14 | Pharmaceutical preparations derived from korean mistletoe |
Country Status (4)
Country | Link |
---|---|
US (1) | US5565200A (en) |
AU (1) | AU5532796A (en) |
CA (1) | CA2174031C (en) |
WO (1) | WO1996032123A1 (en) |
Cited By (11)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
WO1999009837A1 (en) * | 1997-08-28 | 1999-03-04 | Cv Technologies Inc. | Chemical and pharmacological standardization of herbal extracts |
US6025400A (en) * | 1998-08-24 | 2000-02-15 | Marco Polo Technologies | Compositions for treatment of antibiotic-resistant gram-positive bacterial infections and methods for using and preparing the same |
US6063790A (en) * | 1997-07-29 | 2000-05-16 | University Of The Sciences In Philadelphia | Diarylsulfone non-nucleoside reverse transcriptase inhibitors of human immunodeficiency virus |
KR100259231B1 (en) * | 1997-10-28 | 2000-07-01 | 김종배 | Pharmaceutical preparation including active ingredients lectin isolated from Korean Mistletoe |
KR20030028855A (en) * | 2001-10-04 | 2003-04-11 | (주)바이오메디팜 | Anti-cancer composition containing mistletoe extract intensified with lectin |
US6792715B2 (en) | 2001-07-09 | 2004-09-21 | University Of Copenhagen | Methods and cuttings for mass propagation of plant parasites |
WO2004110413A1 (en) * | 2003-06-12 | 2004-12-23 | Won-Bong Park | A composition for an enteric coating of natural product containing lectin |
US6846913B1 (en) | 1999-07-27 | 2005-01-25 | Mistle Biotech Co., Ltd. | Crude extract from Viscum album coloratum, and proteins and lectins isolated therefrom |
KR100490682B1 (en) * | 2002-05-27 | 2005-05-19 | 학교법인 현동학원 | A process for isolating epi-oleanolic acid from Viscum album coloratum |
US6997885B2 (en) | 1998-04-08 | 2006-02-14 | Senorx, Inc. | Dilation devices and methods for removing tissue specimens |
US7572436B1 (en) | 2000-09-11 | 2009-08-11 | Therapro Technologies, Inc. | Thionin as an antineoplastic and immunostimulant |
Families Citing this family (3)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
AU5532696A (en) * | 1995-04-14 | 1996-10-30 | University Of Southern California | Mistletoe extract and method |
DE19639375A1 (en) * | 1996-09-25 | 1998-04-02 | Aar Pharma | Mistletoe dry extracts |
WO2014027958A1 (en) * | 2012-08-14 | 2014-02-20 | Nanyang Technological University | Anti-viral methods and the use of an anti-viral agent |
Citations (12)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US3394120A (en) * | 1963-04-04 | 1968-07-23 | Ciba Geigy Corp | Process of extracting protein from mistletoe and resultant product |
US3472831A (en) * | 1965-02-19 | 1969-10-14 | Ciba Geigy Corp | Process for purifying mistletoe proteins by ultracentrifugation |
US3475402A (en) * | 1965-12-30 | 1969-10-28 | Ciba Geigy Corp | Process of extracting proteins from mistle press juice by carrier-free electrophoresis |
US4525344A (en) * | 1983-08-15 | 1985-06-25 | Tutsky Ronald J | Skin care and shaving composition |
US4590071A (en) * | 1984-09-25 | 1986-05-20 | Xoma Corporation | Human melanoma specific immunotoxins |
US4784849A (en) * | 1983-08-15 | 1988-11-15 | Tutsky Ronald J | Skin care and shaving compositions |
US4861581A (en) * | 1986-12-05 | 1989-08-29 | Cancer Biologics, Inc. | Detection of necrotic malignant tissue and associated therapy |
US4894443A (en) * | 1984-02-08 | 1990-01-16 | Cetus Corporation | Toxin conjugates |
US4966577A (en) * | 1988-03-16 | 1990-10-30 | Allergan, Inc. | Prevention of lens-related tissue growth in the eye |
US5019368A (en) * | 1989-02-23 | 1991-05-28 | Cancer Biologics, Inc. | Detection of necrotic malignant tissue and associated therapy |
US5093475A (en) * | 1988-12-22 | 1992-03-03 | Xoma Corporation | Hindered linking agents derived from 2-iminothiolanes and methods |
US5183904A (en) * | 1988-12-22 | 1993-02-02 | Xoma Corporation | Hindered linking agents and methods |
-
1995
- 1995-04-14 US US08/422,438 patent/US5565200A/en not_active Expired - Fee Related
-
1996
- 1996-04-03 WO PCT/US1996/004577 patent/WO1996032123A1/en active Application Filing
- 1996-04-03 AU AU55327/96A patent/AU5532796A/en not_active Abandoned
- 1996-04-12 CA CA002174031A patent/CA2174031C/en not_active Expired - Lifetime
Patent Citations (12)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US3394120A (en) * | 1963-04-04 | 1968-07-23 | Ciba Geigy Corp | Process of extracting protein from mistletoe and resultant product |
US3472831A (en) * | 1965-02-19 | 1969-10-14 | Ciba Geigy Corp | Process for purifying mistletoe proteins by ultracentrifugation |
US3475402A (en) * | 1965-12-30 | 1969-10-28 | Ciba Geigy Corp | Process of extracting proteins from mistle press juice by carrier-free electrophoresis |
US4525344A (en) * | 1983-08-15 | 1985-06-25 | Tutsky Ronald J | Skin care and shaving composition |
US4784849A (en) * | 1983-08-15 | 1988-11-15 | Tutsky Ronald J | Skin care and shaving compositions |
US4894443A (en) * | 1984-02-08 | 1990-01-16 | Cetus Corporation | Toxin conjugates |
US4590071A (en) * | 1984-09-25 | 1986-05-20 | Xoma Corporation | Human melanoma specific immunotoxins |
US4861581A (en) * | 1986-12-05 | 1989-08-29 | Cancer Biologics, Inc. | Detection of necrotic malignant tissue and associated therapy |
US4966577A (en) * | 1988-03-16 | 1990-10-30 | Allergan, Inc. | Prevention of lens-related tissue growth in the eye |
US5093475A (en) * | 1988-12-22 | 1992-03-03 | Xoma Corporation | Hindered linking agents derived from 2-iminothiolanes and methods |
US5183904A (en) * | 1988-12-22 | 1993-02-02 | Xoma Corporation | Hindered linking agents and methods |
US5019368A (en) * | 1989-02-23 | 1991-05-28 | Cancer Biologics, Inc. | Detection of necrotic malignant tissue and associated therapy |
Non-Patent Citations (37)
Title |
---|
Beuth et al., "Behavior of lymphocyte subsets and expression of activation markers in response to immunotherapy with galactoside-specific lectin from mistletoe in breast cancer patients," Clin. Investig. (1992) 70:658-661. |
Beuth et al., Behavior of lymphocyte subsets and expression of activation markers in response to immunotherapy with galactoside specific lectin from mistletoe in breast cancer patients, Clin. Investig . (1992) 70:658 661. * |
Bloksma, "Stimulation of Humoral and Cellular Immunity by Viscum Preparations," pp. 2-8. |
Bloksma, Stimulation of Humoral and Cellular Immunity by Viscum Preparations, pp. 2 8. * |
Gabius et al., "Cytokines as Mediators in Rationally Standardized Mistletoe Therapy," Abstracts of the Third International Conference of Anticancer Research, 16-20 Oct. 1990, Marathon, Greece, No. 385, pp. 1473-1474. |
Gabius et al., "The galactoside-specific lectin from mistletoe as biological response modifier," Int'l Journal of Oncology, 1, 705-708, 1992. |
Gabius et al., "The immunomodulatory β-Galactoside-Specific Lectin from Mistletoe: Partial Sequence Analysis, Cell and Tissue Binding, and Impact on Intracellular Biosignalling of Monocytic Leukemia Cells," Anticancer Research 12:669-676 (1992). |
Gabius et al., Cytokines as Mediators in Rationally Standardized Mistletoe Therapy, Abstracts of the Third International Conference of Anticancer Research , 16 20 Oct. 1990, Marathon, Greece, No. 385, pp. 1473 1474. * |
Gabius et al., The galactoside specific lectin from mistletoe as biological response modifier, Int l Journal of Oncology , 1, 705 708, 1992. * |
Gabius et al., The immunomodulatory Galactoside Specific Lectin from Mistletoe: Partial Sequence Analysis, Cell and Tissue Binding, and Impact on Intracellular Biosignalling of Monocytic Leukemia Cells, Anticancer Research 12:669 676 (1992). * |
Hajto, "Modulatory Potency of the β-Galactoside-specific Lectin from Mistletoe Extract (Iscador) on the Host Defense System in Vivo in Rabbits and Patients," Cancer Research, 49, 4803-4808, 1991. |
Hajto, Modulatory Potency of the Galactoside specific Lectin from Mistletoe Extract (Iscador) on the Host Defense System in Vivo in Rabbits and Patients, Cancer Research , 49, 4803 4808, 1991. * |
Kayser et al., "Analysis of tumour necrosis factor α-specific, lactose-specific and mistletoe lectinspecific binding sites in human lung carcinomas by labelled ligands," Virchows Archiv A Pathol Anat (1992) 421:345-349. |
Kayser et al., Analysis of tumour necrosis factor specific, lactose specific and mistletoe lectinspecific binding sites in human lung carcinomas by labelled ligands, Virchows Archiv A Pathol Anat (1992) 421:345 349. * |
Khwaja et al., "Biopharmacological Studies of Different Components of Viscum album (Mistletoe)," Abstracts of the Third International Conference of Anticancer Research, pp. 1374-1375, 1990. |
Khwaja et al., "Characterization of biologically active components of Mistletoe," AACR, 1990. |
Khwaja et al., "Characterization of Biologically Active Components of Viscum Album (Mistletoe)," Poster Abstract Form for publication in the Journal of Cancer Research Clinical Oncology, 1989. |
Khwaja et al., "Characterization of cytotoxic lectins isolated from Viscum album, Coloratum," AACR, vol. 30, p. 576, 1989. |
Khwaja et al., "Experimental Basis for the Use of `Iscador` in Cancer Treatment," 13th International Congress of Chemotherapy, Vienna 28th Aug. to 2nd Sep. 1983. |
Khwaja et al., "Isolation of biologically active alkaloids from Korean mistletoe Viscum album, coloratum," Experientia 36 (1980). |
Khwaja et al., "Isolation of Cytotoxic Lectin from Viscum Album, Coloratum," Proceedings of AACR, vol. 28, Mar. 1987, p. 303. |
Khwaja et al., "Isolation of Cytotoxic Proteins from Viscum Album, coloratum," AACR Abstract Form, 1985. |
Khwaja et al., Biopharmacological Studies of Different Components of Viscum album (Mistletoe), Abstracts of the Third International Conference of Anticancer Research , pp. 1374 1375, 1990. * |
Khwaja et al., Characterization of biologically active components of Mistletoe, AACR , 1990. * |
Khwaja et al., Characterization of Biologically Active Components of Viscum Album (Mistletoe), Poster Abstract Form for publication in the Journal of Cancer Research Clinical Oncology , 1989. * |
Khwaja et al., Characterization of cytotoxic lectins isolated from Viscum album, Coloratum, AACR , vol. 30, p. 576, 1989. * |
Khwaja et al., Experimental Basis for the Use of Iscador in Cancer Treatment, 13th International Congress of Chemotherapy , Vienna 28th Aug. to 2nd Sep. 1983. * |
Khwaja et al., Isolation of biologically active alkaloids from Korean mistletoe Viscum album, coloratum , Experientia 36 (1980). * |
Khwaja et al., Isolation of Cytotoxic Lectin from Viscum Album, Coloratum, Proceedings of AACR , vol. 28, Mar. 1987, p. 303. * |
Khwaja et al., Isolation of Cytotoxic Proteins from Viscum Album, coloratum, AACR Abstract Form , 1985. * |
Khwaja et al., Studies on Cytotoxic and Immunologic Effects of Viscum Album (Mistletoe), AACR 22, 253, 1981. * |
Rentea et al., "Biologic Properties of Iscador: A Viscum album Preparation," Laboratory Investigation, vo. 44, No. 1, pp. 43-48, 1981. |
Rentea et al., Biologic Properties of Iscador: A Viscum album Preparation, Laboratory Investigation , vo. 44, No. 1, pp. 43 48, 1981. * |
Rib e reau Gayon et al., Effects of mistletoe ( Viscum album L.) extracts on cultured tumor cells, Experientia 42, pp. 594 599 (1986). * |
Ribereau-Gayon et al., "Effects of mistletoe (Viscum album L.) extracts on cultured tumor cells," Experientia 42, pp. 594-599 (1986). |
S. Krager AG, "Cancer of the Exocrine Pancreas," Oncology, vol. 12, pp. 1-70, 1986. |
S. Krager AG, Cancer of the Exocrine Pancreas, Oncology , vol. 12, pp. 1 70, 1986. * |
Cited By (14)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US6063790A (en) * | 1997-07-29 | 2000-05-16 | University Of The Sciences In Philadelphia | Diarylsulfone non-nucleoside reverse transcriptase inhibitors of human immunodeficiency virus |
US6303630B1 (en) | 1997-07-29 | 2001-10-16 | University Of The Sciences In Philadelphia | Diarylsulfone non-nucleoside reverse transcriptase inhibitors of human immunodeficiency virus |
WO1999009837A1 (en) * | 1997-08-28 | 1999-03-04 | Cv Technologies Inc. | Chemical and pharmacological standardization of herbal extracts |
JP2009292844A (en) * | 1997-08-28 | 2009-12-17 | Fx Life Sciences Ag | Chemical and pharmacological standardization of herbal extract |
KR100259231B1 (en) * | 1997-10-28 | 2000-07-01 | 김종배 | Pharmaceutical preparation including active ingredients lectin isolated from Korean Mistletoe |
US6997885B2 (en) | 1998-04-08 | 2006-02-14 | Senorx, Inc. | Dilation devices and methods for removing tissue specimens |
US6025400A (en) * | 1998-08-24 | 2000-02-15 | Marco Polo Technologies | Compositions for treatment of antibiotic-resistant gram-positive bacterial infections and methods for using and preparing the same |
US6316033B1 (en) | 1998-08-24 | 2001-11-13 | Marco Polo Technologies | Compositions for treatment of antibiotic-resistant gram-positive bacterial infections and methods for using and preparing the same |
US6846913B1 (en) | 1999-07-27 | 2005-01-25 | Mistle Biotech Co., Ltd. | Crude extract from Viscum album coloratum, and proteins and lectins isolated therefrom |
US7572436B1 (en) | 2000-09-11 | 2009-08-11 | Therapro Technologies, Inc. | Thionin as an antineoplastic and immunostimulant |
US6792715B2 (en) | 2001-07-09 | 2004-09-21 | University Of Copenhagen | Methods and cuttings for mass propagation of plant parasites |
KR20030028855A (en) * | 2001-10-04 | 2003-04-11 | (주)바이오메디팜 | Anti-cancer composition containing mistletoe extract intensified with lectin |
KR100490682B1 (en) * | 2002-05-27 | 2005-05-19 | 학교법인 현동학원 | A process for isolating epi-oleanolic acid from Viscum album coloratum |
WO2004110413A1 (en) * | 2003-06-12 | 2004-12-23 | Won-Bong Park | A composition for an enteric coating of natural product containing lectin |
Also Published As
Publication number | Publication date |
---|---|
CA2174031C (en) | 2002-12-17 |
AU5532796A (en) | 1996-10-30 |
CA2174031A1 (en) | 1996-10-15 |
WO1996032123A1 (en) | 1996-10-17 |
Similar Documents
Publication | Publication Date | Title |
---|---|---|
US6379714B1 (en) | Pharmaceutical grade botanical drugs | |
Kincade et al. | Growth of B-lymphocytes clones in semisolid culture is mitogen dependent. | |
US5565200A (en) | Pharmaceutical preparations derived from korean mistletoe | |
Parmely et al. | In vitro studies on the T-lymphocyte population of human milk. | |
KR100780521B1 (en) | Processes of Making North American Ginseng Fractions, Products Containing Them, and Use as Immunomodulators | |
US4571336A (en) | Immune stimulation | |
US5780037A (en) | Mistletoe extract and method | |
US6676980B2 (en) | Method for preparing an olea europaea extract and method of use of the same | |
US5547674A (en) | Pharmaceutical preparations derived from European mistletoe | |
Viana et al. | Antinociceptive activity of sulfated carbohydrates from the red algae Bryothamnion seaforthii (Turner) Kütz. and B. triquetrum (SG Gmel.) M. Howe | |
WO1996032122A9 (en) | Mistletoe extract and method | |
US5096708A (en) | Medical preparation containing as active agent a component from thuja plants which comprises polysaccharides | |
CA2448044A1 (en) | Korean acanthopanax senticosus extract, protein extract, crude protein-polysaccharide which were extracted from korean acanthopanax senticosus, and immunoregulating compositions comprising the same and use thereof | |
EP1200482A1 (en) | Hematopoietic arabinogalactan composition | |
JP3215309B2 (en) | Method for producing granulocyte macrophage colony stimulating factor | |
CN104974236A (en) | Scorpion venom polypeptide B4, and separation and purification method and application thereof | |
US7309501B2 (en) | Conditioned media to inhibit growth of tumor cells | |
JPH11302191A (en) | Immunoactivator and antitumor agent containing extract from lyophyllum decastes (fr.) sing. as active ingredient | |
RU2195308C1 (en) | Method of preparing substance showing immunostimulating, antiviral and antibacterial activity, substance obtained by this method and pharmaceutical composition based on thereof | |
MXPA01008280A (en) | High molecular weight extracts of convolvulus arvensis (field bindweed). | |
KR100392996B1 (en) | Cell growth regulators | |
NO850152L (en) | PROCEDURE FOR MANUFACTURING HUMAN, EVEN CANCER REGULATORY FACTOR. | |
Myhre | Exploring growth-inhibitory and immuno-stimulatory activity in British Columbia wild mushrooms and lichens. | |
AU2079883A (en) | Immune stimulator | |
RU2272810C2 (en) | Agent for stem cell activation |
Legal Events
Date | Code | Title | Description |
---|---|---|---|
AS | Assignment |
Owner name: UNIVERSITY OF SOUTHERN CALIFORNIA, CALIFORNIA Free format text: ASSIGNMENT OF ASSIGNORS INTEREST;ASSIGNOR:KHWAJA, TASNEEM A.;REEL/FRAME:007615/0482 Effective date: 19950414 |
|
AS | Assignment |
Owner name: UNIVERITY OF SOUTHERN CALIFORNIA, CALIFORNIA Free format text: ASSIGNMENT OF ASSIGNORS INTEREST;ASSIGNOR:KHWAJA, TASNEEM A.;REEL/FRAME:008639/0094 Effective date: 19970723 Owner name: PHARMAPRINT INC., CALIFORNIA Free format text: ASSIGNMENT OF ASSIGNORS INTEREST;ASSIGNOR:FRIEDMAN, ELLIOT P.;REEL/FRAME:008639/0097 Effective date: 19970723 |
|
FEPP | Fee payment procedure |
Free format text: PAYOR NUMBER ASSIGNED (ORIGINAL EVENT CODE: ASPN); ENTITY STATUS OF PATENT OWNER: SMALL ENTITY |
|
FPAY | Fee payment |
Year of fee payment: 4 |
|
AS | Assignment |
Owner name: MONTECITO LEASING GROUP, LLC, CALIFORNIA Free format text: ASSIGNMENT OF ASSIGNORS INTEREST;ASSIGNOR:PHARMAPRINT, INC.;REEL/FRAME:011058/0124 Effective date: 20000508 |
|
REMI | Maintenance fee reminder mailed | ||
LAPS | Lapse for failure to pay maintenance fees | ||
STCH | Information on status: patent discontinuation |
Free format text: PATENT EXPIRED DUE TO NONPAYMENT OF MAINTENANCE FEES UNDER 37 CFR 1.362 |
|
FP | Lapsed due to failure to pay maintenance fee |
Effective date: 20041015 |